Evidence map›Paper›PMID 39187464›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2025

Mutual Amplification of GLI2/Hedgehog and Transcription Factor JUN/AP-1 Signaling in Fibroblasts in Systemic Sclerosis: Potential Implications for Combined Therapies.

Christina Bergmann, Sara Chenguiti Fakhouri, Thuong Trinh-Minh, Tim Filla, Aleix Rius Rigau, Arif B Ekici, Benita Merlevede, Ludwig Hallenberger, Honglin Zhu, Clara Dees and 11 more

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Identification and Validation of Hub Genes in Hidradenitis Suppurativa.Clinical, cosmetic and investigational dermatology · 2025
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Christina BergmannDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.ORCID 0000-0001-5257-9171
Sara Chenguiti FakhouriDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
Thuong Trinh-MinhHiller Research Center, University Hospital Düsseldorf and Heinrich Heine University, Düsseldorf, Germany.
Tim FillaHiller Research Center, University Hospital Düsseldorf and Heinrich Heine University, Düsseldorf, Germany.
Aleix Rius RigauDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
Arif B EkiciInstitute of Human Genetics, Friedrich Alexander Universität Erlangen-Nürnberg, and Uniklinikum Erlangen, Erlangen, Germany.
Benita MerlevedeDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
Ludwig HallenbergerDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
Honglin ZhuXiangya Hospital, Central South University, Changsha, China.ORCID 0000-0001-8724-2835
Clara DeesDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
Alexandru-Emil MateiHiller Research Center, University Hospital Düsseldorf and Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0003-1248-3145
Janina AuthDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
Andrea-Hermina GyörfiHiller Research Center, University Hospital Düsseldorf and Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0002-4960-3369
Xiang ZhouHiller Research Center, University Hospital Düsseldorf and Heinrich Heine University, Düsseldorf, Germany.
Simon RauberDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
Aline BozecDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
Nicholas DickelFriedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Chunguang LiangFriedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Meik KunzFriedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, and Fraunhofer Institute for Toxicology and Experimental Medicine and Fraunhofer Cluster of Excellence Immune-Mediated Diseases, Hannover, Germany.
Georg SchettDeutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.ORCID 0000-0001-8740-9615
Jörg H W DistlerHiller Research Center, University Hospital Düsseldorf and Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0001-7408-9333

Funding

Bundesministerium für Bildung und Forschung MASCARA programBundesministerium für Bildung und Forschung TP2(01EC1903A),iIMMUNE_ACS(01EO2105)Clinician Scientist Program project424726560(imagingCyTOF)Clinician Scientist Program project441730715(LeicaStellaris8Microscope)Deutsche Forschungsgemeinschaft BE7036/2-1Deutsche Forschungsgemeinschaft BE7036/5-1Deutsche Forschungsgemeinschaft DI 1537/Deutsche Forschungsgemeinschaft DI 1537/17-1Deutsche Forschungsgemeinschaft DI 1537/20-1Deutsche Forschungsgemeinschaft DI 1537/22-1Deutsche Forschungsgemeinschaft GRK 2740 (B02 to M.K.)),Deutsche Forschungsgemeinschaft NOTICE(RA2506/7-21)Deutsche Forschungsgemeinschaft project324392634(B04),project324392634,GRK2740(B02toM.K.)Deutsche Forschungsgemeinschaft SFB CRC1181 (project A01 and C01)Deutsche Forschungsgemeinschaft SFB TR221Else-Kröner-Fresenius-Stiftung 2014_A184Else-Kröner-Fresenius-Stiftung 2014_A47Fraunhofer Cluster of Excellence Immune-Mediated DiseasesInterdisziplinäres Zentrum für Klinische Forschung, Erlangen 21-11-09-1-BergmannInterdisziplinäres Zentrum für Klinische Forschung, Erlangen A79Interdisziplinäres Zentrum für Klinische Forschung, Erlangen Clinician Scientist Program (Bergmann)Interdisziplinäres Zentrum für Klinische Forschung, Erlangen grant 14-12-17-1-BergmannWilhelm-Sander-Stiftung 2013.056.1
6 · The paper itself

Abstract

objectiveDeregulation of the cJUN/AP-1 and hedgehog/GLI2 signaling pathways has been implicated in fibroblast activation in systemic sclerosis (SSc). However, the consequences of their concomitant up-regulation are unknown. Here, we tested the hypothesis that mutual amplification of both pathways might drive persistent fibroblast activation.

methodsCultured fibroblasts and skin sections of patients with diffuse SSc and healthy volunteers were analyzed. cJUN/AP-1 signaling and hedgehog/GLI2 signaling were inhibited using knockdown and pharmacologic approaches. Hedgehog signaling was activated in mice by fibroblast-specific overexpression of constitutively active Smoothened.

resultscJUN and GLI2 are concomitantly up-regulated and colocalize in fibroblasts of patients with SSc compared to healthy controls. Activation of hedgehog/GLI2 signaling induces the expression of cJUN in vitro and in vivo, whereas inactivation of GLI2 inhibits cJUN expression. Likewise, inactivation of cJUN impairs the expression of GLI2. This mutual regulation occurs at the level of transcription with binding of cJUN and GLI2 to specific binding motifs. Interference with this mutual amplification of cJUN signaling and GLI2 signaling inhibits fibroblast activation and collagen release: Inhibition of cJUN/AP-1 signaling ameliorates hedgehog-induced fibroblast activation and skin fibrosis in Smo

conclusionThe transcription factors cJUN and GLI2 reinforce each other's activity to promote fibroblast activation in SSc. Interruption of this crosstalk by combined inhibition of both pathways exerts additive antifibrotic effects at well-tolerated doses.

Indexed as

FibroblastsHedgehog ProteinsProto-Oncogene Proteins c-junScleroderma, SystemicSignal TransductionTranscription Factor AP-1Zinc Finger Protein Gli2AnimalsCase-Control StudiesCells, CulturedFemaleHumansMiceNuclear ProteinsSkinSmoothened ReceptorGLI2 protein, humanHedgehog ProteinsNuclear ProteinsProto-Oncogene Proteins c-junSmoothened ReceptorTranscription Factor AP-1Zinc Finger Protein Gli2

Identifiers

PMID39187464
PMCPMC11684997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.